Discount swings NICE decision, drug will compete with GSK rival
Managed access scheme will control costs to NHS.
Developments that promise to improve clinical research in Brazil.
Sobi’s Xiapex recommended after reassessment.
RA drug backed after manufacturer offered discount.
Concerns that NICE will reject Kisqali like it did Ibrance.
Reports also suggest Trump’s pricing plans may be pro-industry.
Assessing the global challenges inhibiting immuno-oncology market access.